JP2010535242A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010535242A5 JP2010535242A5 JP2010520185A JP2010520185A JP2010535242A5 JP 2010535242 A5 JP2010535242 A5 JP 2010535242A5 JP 2010520185 A JP2010520185 A JP 2010520185A JP 2010520185 A JP2010520185 A JP 2010520185A JP 2010535242 A5 JP2010535242 A5 JP 2010535242A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- disorder
- tcg
- disease
- aacg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 239000013566 allergen Substances 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- -1 vaccines Substances 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 108010041986 DNA Vaccines Proteins 0.000 claims 2
- 229940021995 DNA vaccine Drugs 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 208000037883 airway inflammation Diseases 0.000 claims 2
- 229960004784 allergens Drugs 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000009286 beneficial effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims 1
- WERYXYBDKMZEQL-UHFFFAOYSA-N 1,4-butanediol Substances OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 claims 1
- 108091028664 Ribonucleotide Proteins 0.000 claims 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims 1
- 239000002336 ribonucleotide Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95325107P | 2007-08-01 | 2007-08-01 | |
| US60/953,251 | 2007-08-01 | ||
| US98360107P | 2007-10-30 | 2007-10-30 | |
| US60/983,601 | 2007-10-30 | ||
| US98715107P | 2007-11-12 | 2007-11-12 | |
| US60/987,151 | 2007-11-12 | ||
| US1529207P | 2007-12-20 | 2007-12-20 | |
| US61/015,292 | 2007-12-20 | ||
| PCT/US2008/071738 WO2009018431A2 (en) | 2007-08-01 | 2008-07-31 | Novel synthetic agonists of tlr9 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014120860A Division JP5816720B2 (ja) | 2007-08-01 | 2014-06-11 | Ｔｌｒ９の新規な合成アゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010535242A JP2010535242A (ja) | 2010-11-18 |
| JP2010535242A5 true JP2010535242A5 (cg-RX-API-DMAC7.html) | 2013-05-02 |
| JP5563455B2 JP5563455B2 (ja) | 2014-07-30 |
Family
ID=40305273
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010520185A Active JP5563455B2 (ja) | 2007-08-01 | 2008-07-31 | Ｔｌｒ９の新規な合成アゴニスト |
| JP2014120860A Active JP5816720B2 (ja) | 2007-08-01 | 2014-06-11 | Ｔｌｒ９の新規な合成アゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014120860A Active JP5816720B2 (ja) | 2007-08-01 | 2014-06-11 | Ｔｌｒ９の新規な合成アゴニスト |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7960362B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP2821488B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5563455B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20100053598A (cg-RX-API-DMAC7.html) |
| CN (3) | CN102864151B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008282172B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0813981A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2693266C (cg-RX-API-DMAC7.html) |
| ES (2) | ES2539353T3 (cg-RX-API-DMAC7.html) |
| IN (1) | IN2010KN00195A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2468819C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009018431A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7276489B2 (en) * | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
| US8158768B2 (en) * | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
| US7354907B2 (en) * | 2003-02-07 | 2008-04-08 | Idera Pharmaceuticals, Inc. | Short immunomodulatory oligonucleotides |
| EP2371834B1 (en) * | 2003-06-11 | 2016-02-17 | Idera Pharmaceuticals, Inc. | Stabilized immunomodulatory oligonucleotides |
| US20060074040A1 (en) * | 2003-07-15 | 2006-04-06 | Hybridon, Inc. | Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy |
| US7615539B2 (en) * | 2003-09-25 | 2009-11-10 | Coley Pharmaceutical Group, Inc. | Nucleic acid-lipophilic conjugates |
| WO2009018431A2 (en) * | 2007-08-01 | 2009-02-05 | Idera Pharmaceuticals, Inc. | Novel synthetic agonists of tlr9 |
| WO2010088395A2 (en) * | 2009-01-30 | 2010-08-05 | Idera Pharmaceuticals, Inc. | Novel synthetic agonists of tlr9 |
| US8883174B2 (en) | 2009-03-25 | 2014-11-11 | The Board Of Regents, The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
| US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
| US20120045433A1 (en) * | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
| US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
| WO2014110081A1 (en) * | 2013-01-08 | 2014-07-17 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
| AR095882A1 (es) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
| GB2514591A (en) * | 2013-05-30 | 2014-12-03 | Mologen Ag | Predictive biomarker for cancer therapy |
| WO2015187966A1 (en) | 2014-06-04 | 2015-12-10 | Aurasense Therapeutics, Llc | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| US20170298178A1 (en) * | 2014-09-12 | 2017-10-19 | Vantage Specialty Chemicals, Inc. | Derivatives of 1,3-propanediol |
| US10286065B2 (en) | 2014-09-19 | 2019-05-14 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
| JP6991857B2 (ja) * | 2014-10-10 | 2022-01-13 | イデラ ファーマシューティカルズ インコーポレイテッド | Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療 |
| WO2016081911A2 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| WO2017052403A1 (ru) * | 2015-09-25 | 2017-03-30 | Анатолий Викторович ЗАЗУЛЯ | Изготовление таблетки с механизмом повышения терапевтической эффективности лекарственного средства нанодозой микрорнк |
| US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
| CA3036978A1 (en) | 2016-09-15 | 2018-03-22 | Idera Pharmaceuticals, Inc. | Immune modulation with tlr9 agonists for cancer treatment |
| US20180193003A1 (en) | 2016-12-07 | 2018-07-12 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3046019A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a tlr modulator |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| US11427615B2 (en) | 2017-07-05 | 2022-08-30 | Xdcexplorer (Shanghai) Co., Ltd. | Peptide compound and application thereof, and composition containing peptide compound |
| WO2019066571A2 (ko) | 2017-09-28 | 2019-04-04 | 연세대학교 산학협력단 | 골수유래 면역반응 억제세포의 제조방법, 이에 의해 제조된 골수유래 면역반응 억제세포 및 그 용도 |
| CA3145889A1 (en) | 2019-07-05 | 2021-01-14 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| WO2021174024A1 (en) | 2020-02-28 | 2021-09-02 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| US20230226050A1 (en) | 2020-07-02 | 2023-07-20 | Viiv Healthcare Company | Method of achieving hiv viral remission using long-acting antiretroviral agents |
| EP4192506A1 (en) | 2020-08-07 | 2023-06-14 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| ATE432348T1 (de) * | 1997-06-06 | 2009-06-15 | Univ California | Inhibitoren von immunstimulatorischen dna sequenz aktivität |
| US6562798B1 (en) * | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| US6503734B1 (en) * | 2000-07-26 | 2003-01-07 | Cognis Corporation | Cytochrome b5 gene and protein of Candida tropicalis and methods relating thereto |
| US6673613B2 (en) * | 2000-07-26 | 2004-01-06 | Cognis Corporation | Use of CYP52A2A promoter to increase gene expression in yeast |
| RU2194502C2 (ru) * | 2000-12-27 | 2002-12-20 | Наровлянский Александр Наумович | Иммуномодулятор - метаболик - детоксикант - адаптоген - радиопротектор |
| JP4188687B2 (ja) * | 2000-12-27 | 2008-11-26 | ダイナバックス テクノロジーズ コーポレイション | 免疫変調ポリヌクレオチド及びその使用法 |
| CN100334228C (zh) * | 2001-06-21 | 2007-08-29 | 戴纳瓦克斯技术公司 | 嵌合免疫调制化合物及其使用方法 |
| US7276489B2 (en) | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
| KR101178816B1 (ko) * | 2002-12-23 | 2012-09-07 | 다이나박스 테크놀로지 코퍼레이션 | 면역자극성 서열 올리고뉴클레오타이드 및 이의 이용방법 |
| EP1620070A2 (en) * | 2003-04-29 | 2006-02-01 | Centocor, Inc. | Toll-like receptor 9 effector agents and uses thereof |
| EP2371834B1 (en) * | 2003-06-11 | 2016-02-17 | Idera Pharmaceuticals, Inc. | Stabilized immunomodulatory oligonucleotides |
| US20050244410A1 (en) * | 2004-04-29 | 2005-11-03 | Ashlyn Bassiri | Toll-like receptor 9 effector agents and uses thereof |
| RU2007101039A (ru) * | 2004-06-15 | 2008-07-20 | Айдера Фармасьютикалз | Иммуностимулирующие олигонуклеотидные мультимеры |
| WO2007047396A2 (en) * | 2005-10-12 | 2007-04-26 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
| EP2371956A3 (en) * | 2005-11-07 | 2012-01-04 | Idera Pharmaceuticals | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
| US7786089B2 (en) * | 2005-12-20 | 2010-08-31 | Idera Pharmaceuticals, Inc. | Immunostimulatory activity of immune modulatory oligonucleotides (IMO™) containing different lengths of palindromic segments |
| CN101610671A (zh) * | 2006-12-12 | 2009-12-23 | 艾德拉药物股份有限公司 | 合成的tlr9激动剂 |
| WO2008131074A1 (en) * | 2007-04-19 | 2008-10-30 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders |
| WO2009018431A2 (en) * | 2007-08-01 | 2009-02-05 | Idera Pharmaceuticals, Inc. | Novel synthetic agonists of tlr9 |
-
2008
- 2008-07-31 WO PCT/US2008/071738 patent/WO2009018431A2/en not_active Ceased
- 2008-07-31 IN IN195KON2010 patent/IN2010KN00195A/en unknown
- 2008-07-31 EP EP14183548.8A patent/EP2821488B1/en active Active
- 2008-07-31 EP EP08796942A patent/EP2173912A4/en not_active Withdrawn
- 2008-07-31 EP EP20130171674 patent/EP2650369B1/en active Active
- 2008-07-31 KR KR1020107004710A patent/KR20100053598A/ko not_active Withdrawn
- 2008-07-31 CA CA2693266A patent/CA2693266C/en active Active
- 2008-07-31 ES ES13171674.8T patent/ES2539353T3/es active Active
- 2008-07-31 CN CN201210311690.3A patent/CN102864151B/zh not_active Expired - Fee Related
- 2008-07-31 AU AU2008282172A patent/AU2008282172B2/en active Active
- 2008-07-31 CN CN2008801098527A patent/CN101878311A/zh active Pending
- 2008-07-31 BR BRPI0813981A patent/BRPI0813981A2/pt not_active IP Right Cessation
- 2008-07-31 ES ES14183548.8T patent/ES2585239T3/es active Active
- 2008-07-31 US US12/183,439 patent/US7960362B2/en active Active
- 2008-07-31 JP JP2010520185A patent/JP5563455B2/ja active Active
- 2008-07-31 CN CN201510303003.7A patent/CN105177014B/zh not_active Expired - Fee Related
- 2008-07-31 RU RU2010107207/10A patent/RU2468819C2/ru active
-
2011
- 2011-06-08 US US13/156,140 patent/US8361986B2/en not_active Expired - Fee Related
-
2014
- 2014-06-11 JP JP2014120860A patent/JP5816720B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010535242A5 (cg-RX-API-DMAC7.html) | ||
| JP7213566B2 (ja) | 病原体ワクチンならびにその製造および使用方法 | |
| JP2013507905A5 (cg-RX-API-DMAC7.html) | ||
| RU2010107207A (ru) | Новые синтетические агонисты tlr9 | |
| JP6697384B2 (ja) | 予防的および治療的使用のための免疫刺激剤としての球状の核酸ベース構築物 | |
| JP4942646B2 (ja) | 免疫賦活オリゴヌクレオチドマルチマー | |
| ES2380796T3 (es) | Oligonucleótidos inmunoestimuladores y sus usos. | |
| JP2010532996A5 (cg-RX-API-DMAC7.html) | ||
| AU2006304205C1 (en) | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | |
| JP2008501807A5 (cg-RX-API-DMAC7.html) | ||
| ES2314099T3 (es) | Oligonucleotidos inmunoestimulantes con motivos combinados con actividad mejorada. | |
| JP5455629B2 (ja) | 増強された免疫刺激活性を有する疎水性Ｔ類似体を含有するＣｐＧオリゴヌクレオチド類似体 | |
| JP2010512421A5 (cg-RX-API-DMAC7.html) | ||
| CA2752694A1 (en) | Synthetic rna-based agonists of tlr7 | |
| US20160194642A1 (en) | Spherical nucleic acid-based constructs as immunoregulatory agents | |
| ES2486298T3 (es) | Análogos de oligonucleótidos inmunoestimuladores que contienen azúcares modificados | |
| US12473553B2 (en) | RNA nanostructures and methods of making and using RNA nanostructures | |
| JP2009515823A5 (cg-RX-API-DMAC7.html) | ||
| HRP20150566T1 (hr) | Kompozicija za inhibiciju ekspresije gena i njegova upotreba | |
| JP2010507386A (ja) | オリゴリボヌクレオチドおよびその使用 | |
| JP2010504982A (ja) | Ｔｌｒのリガンドと抗ウイルス剤との組成物 | |
| CN101160401A (zh) | 免疫刺激寡核苷酸 | |
| Mohri et al. | DNA nanotechnology-based development of delivery systems for bioactive compounds | |
| WO2017007027A1 (ja) | 免疫刺激オリゴヌクレオチド複合体 | |
| JP2013532976A5 (cg-RX-API-DMAC7.html) |